Search

Your search keyword '"Kivity, S."' showing total 649 results
Start Over Author "Kivity, S."
649 results on '"Kivity, S."'

1. POS1198 EPIDEMIOLOGY OF VEXAS SYNDROME IN ISRAEL – A HIGH PREVALENCE OF UBA1 p.M41V PATHOGENIC VARIANT IN ISRAELI VEXAS PATIENTS

Author

Eviatar, T., primary, Zisapel, M., additional, Feinstein Goren, N., additional, Sagy, I., additional, Kivity, S., additional, Lidar, M., additional, Bieber, A., additional, Tayer-Shifman, O., additional, Peleg, H., additional, Ozeri, D., additional, Shamash, J., additional, Pras, E., additional, Baris-Feldman, H., additional, Edel, Y., additional, Dortort Lazar, A., additional, Wolach, O., additional, Molad, Y., additional, Stremer, G., additional, Naffa, M. E., additional, Porges, T., additional, and Elkayam, O., additional

Published
2024
Full Text
View/download PDF

3. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study

Author

Keith, P., Yang, W., Maurer, M., Martinez-Saguer, I., Farkas, H., Reshef, A., Kivity, S., Moldovan, D., Caballero, T., Guilarte, M., Hernandez, M.D., González-Quevedo, M.T., Banerji, A., Bernstein, J., Bewtra, A., Craig, T., Fineman, S., Gower, R., Jacobs, J., Johnston, D., Kashkin, J., Li, H.H., Lumry, W.R., Manning, M., McNeil, D., Melamed, I., Mumneh, N., Nickel, T., Panuto, J., Soteres, D., Tachdjian, R., Offenberger, J., Wedner, J., Lumry, William R., Martinez-Saguer, Inmaculada, Yang, William H., Bernstein, Jonathan A., Jacobs, Joshua, Moldovan, Dumitru, Riedl, Marc A., Johnston, Douglas T., Li, H. Henry, Tang, Yongqiang, Schranz, Jennifer, Lu, Peng, Vardi, Moshe, and Farkas, Henriette

Published
2019
Full Text
View/download PDF

6. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting

Author

Aberer, W., Grumach, A., Bygum, A., Blanchard Delaunay, C., Bouillet, L., Coppere, B., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Arnolds, J., Aygören-Pürsün, E., Baş, M., Bauer, A., Bork, K., Martinez, I., Maurer, M., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Baeza, M.L., Caballero, T., Cabañas, R., Guilarte, M., Hernandez de Rojas, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Sáenz de San Pedro, B., Bjorkander, J., Helbert, M., Longhurst, H.J., Zanichelli, Andrea, Longhurst, Hilary J., Maurer, Marcus, Bouillet, Laurence, Aberer, Werner, Fabien, Vincent, Andresen, Irmgard, and Caballero, Teresa

Published
2016
Full Text
View/download PDF

13. Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

Author

Zanichelli, A., Maurer, M., Aberer, W., Caballero, T., Longhurst, H. J., Bouillet, L., Fabien, V., Andresen, I., Grumach, A., Bygum, A., Blanchard Delaunay, C., Boccon-Gibod, I., Coppere, B., Du Thanh, A., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Aygören-Pürsün, E., Bas, M., Bauer, A., Bork, K., Greve, J., Magerl, M., Martinez Saguer, I., Strassen, U., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Triggiani, M., Baeza, L., Cabañas, R., Gala Ortiz, G., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marques, L., Saenz de San Pedro, B., Björkander, J., Bethune, C., Garcez, T., Zanichelli, A., Maurer, M., Aberer, W., Caballero, T., Longhurst, H. J., Bouillet, L., Fabien, V., Andresen, I., Grumach, A., Bygum, A., Blanchard Delaunay, C., Boccon-Gibod, I., Coppere, B., Du Thanh, A., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Aygören-Pürsün, E., Bas, M., Bauer, A., Bork, K., Greve, J., Magerl, M., Martinez Saguer, I., Strassen, U., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Triggiani, M., Baeza, L., Cabañas, R., Gala Ortiz, G., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marques, L., Saenz de San Pedro, B., Björkander, J., Bethune, C., and Garcez, T.

Subjects
safety, 0301 basic medicine, real-world, medicine.medical_specialty, Immunology, Brief Communication, Off-label use, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Icatibant, Internal medicine, angioedema, icatibant, Immunology and Allergy, Medicine, Reflux esophagitis, Adverse effect, Pregnancy, Angioedema, business.industry, real‐world, medicine.disease, 030104 developmental biology, 030228 respiratory system, chemistry, Anesthesia, Observational study, Long term safety, medicine.symptom, business
Abstract

The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real‐world setting. We analyzed safety data from 3025 icatibant‐treated attacks in 557 patients (enrolled between July 2009 and February 2015). Icatibant was generally well tolerated. Excluding off‐label use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs). The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinal disorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icatibant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to icatibant. Notably, no SAEs related to icatibant occurred in patients with cardiovascular disease, nor in those using icatibant at a frequency above label guidelines. Additionally, no major differences were noted in AEs occurring in on‐label vs off‐label icatibant users.

Published
2017
Full Text
View/download PDF

14. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

Author

Cicardi, M., Banerji, A., Bracho, F., Malbran, A., Rosenkranz, B., Riedi, M., Bork, K., Lumry, W., Aberer, W., Bier, H., Bas, M., Greve, J., Hoffmann, T.K., Farkas, H., Reshef, A., Ritchie, B., Yang, W., Grabbe, J., Kivity, S., Kreuz, W., Levy, R.J., Luger, T., Obtulowicz, K., Schmid-Grendelmeier, P., Bull, C., Sitkauskiene, B., Smith, W.B., Toubi, E., Werner, S., Anne, S., Bjorkander, J., Bouillet, L., Cillari, E., Hurewitz, D., Jacobson, K.W., Katelaris. C.H., Maurer, M., Merk, H., Bernstein, J.A., Feighery, C., Floccard, B., Gleich, G., Hebert, J., Kaatz, M.Keith, P., Kirkpatrick, C.H., Langton, D., Martin, L., Pichler, C., Resnick, D., Wombolt, D., Romero, D.S. Fernandez, Zanichelli, A.Arcoleo, F., Knolle, J., Kravec, I., Dong, L., Zimmermann, J., Rosen. K., and Fan, W.-T

Subjects
Tranexamic acid -- Health aspects, Tranexamic acid -- Comparative analysis, Angioneurotic edema -- Genetic aspects, Angioneurotic edema -- Drug therapy, Bradykinin -- Health aspects, Bradykinin -- Comparative analysis
Abstract

A study was conducted to evaluate the efficacy and safety of icatibant, a new bradykinin-receptor antagonist in the treatment of hereditary angioedema. Results indicated that in the case of such patients, icatibant was found to be quite effective and having positive outcomes as compared to placebo or tranexamic acid.

Published
2010

21. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Author

Longhurst, H, Cicardi, M, Craig, T, Bork, K, Grattan, C, Baker, J, Li, HH, Reshef, A, Bonner, J, Bernstein, JA, Anderson, J, Lumry, WR, Farkas, H, Katelaris, CH, Sussman, GL, Jacobs, J, Riedl, M, Manning, ME, Hebert, J, Keith, PK, Kivity, S, Neri, S, Levy, DS, Baeza, ML, Nathan, R, Schwartz, LB, Caballero, T, Yang, W, Crisan, I, Hernandez, MD, Hussain, I, Tarzi, M, Ritchie, B, Kralickova, P, Guilarte, M, Rehman, SM, Banerji, A, Gower, RG, Bensen-Kennedy, D, Edelman, J, Feuersenger, H, Lawo, JP, Machnig, T, Pawaskar, D, Pragst, I, Zuraw, BL, COMPACT Investigators, Institut Català de la Salut, [Longhurst H] Barts Health NHS Trust, London, United Kingdom. [Cicardi M] Ospedale Luigi Sacco–U.O. Medicina Generale, Milan, Italy. [Craig T] Department of Medicine and Pediatrics, Penn State Hershey Allergy, Asthma, and Immunology, Hershey, United States. [Bork K] Johannes Gutenberg University Mainz, Mainz, Germany. [Grattan C] St. John’s Institute of Dermatology, Guy’s Hospital, London, United Kingdom. [Baker J] Baker Allergy, Asthma and Dermatology Research Center, Portland, United States. [Guilarte M] Hospital Universitari Vall d'Hebron, Barcelona, Spain., Vall d'Hebron Barcelona Hospital Campus, and Hospital Universitari Vall d'Hebron

Subjects
Male, aminoácidos, péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS], 0301 basic medicine, Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores], Enzims proteolítics - Inhibidors, Self Administration, Severity of Illness Index, law.invention, C1-inhibitor, Subcutaneous injection, 0302 clinical medicine, Randomized controlled trial, law, Cross-Over Studies, Hereditary Angioedema Types I and II, biology, Edema - Prevenció, General Medicine, Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas, Hereditary [DISEASES], Anesthesia, Hereditary angioedema, Other subheadings::Other subheadings::/administration & dosage [Other subheadings], Female, Amino Acids, Peptides, and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS], medicine.symptom, Complement C1 Inhibitor Protein, enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES], Adult, Risk, medicine.medical_specialty, Injections, Subcutaneous, Aminoácidos, Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS], Placebo, Other subheadings::Other subheadings::/prevention & control [Other subheadings], 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections, Subcutaneous [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores], Dose-Response Relationship, Drug, Angioedema, business.industry, Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Injeccions hipodèrmiques, medicine.disease, Crossover study, Clinical trial, terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], 030104 developmental biology, 030228 respiratory system, biology.protein, business
Abstract

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the efficacy and safety of self-administered subcutaneous CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks in a consecutive 2-month period within 3 months before screening. We randomly assigned the patients to one of four treatment sequences in a crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo, or vice versa. The primary efficacy end point was the number of attacks of angioedema. Secondary efficacy end points were the proportion of patients who had a response (≥50% reduction in the number of attacks with CSL830 as compared with placebo) and the number of times that rescue medication was used. RESULTS: Of the 90 patients who underwent randomization, 79 completed the trial. Both doses of CSL830, as compared with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42 attacks per month; 95% confidence interval [CI], -3.38 to -1.46; and mean difference with 60 IU, -3.51 attacks per month; 95% CI, -4.21 to -2.81; P

Published
2017
Full Text
View/download PDF

23. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks

Author

Zuraw, B, Katelaris, C, Sussman, G, Keith, PK, Yang, W, Hebert, J, Hanzlikova, J, Staubach-Renz, P, Martinez-Saguer, I, Magerl, M, Aygoren-Pursun, E, Farkas, H, Reshef, A, Kivity, S, Neri, S, Crisan, I, Caballero, T, Baeza, ML, Hernandez, MD, Li, H, Lumry, W, Bernstein, JA, Hussain, I, Anderson, J, Schwartz, LB, Jacobs, J, Manning, M, Levy, D, Riedl, M, Christiansen, S, Zuraw, BL, Cicardi, M, Craig, T, Longhurst, H, Grattan, C, Bork, K, Kreuz, W, Jacobs, I, Pragst, I, Herget, S, Dalton, S, Clement, C, Mycroft, S, Pawaskar, D, Zhang, Y, Machnig, T, Waldhauser, H, Feuersenger, H, Lawo, JP, Lang, D, Hoernlein, S, Mildenberger, M, Foeller, K, Ellis, F, Wood, D, Walsh, M, Qu, QL, Mueller-Stark, K, Feussner, A, Kalina, U, Ma, X, Rigsby, S, Scheffler, E, Fischer, JF, Kolb, C, Katelaris, CH, Frankum, B, Keat, K, Philip, B, Lee, JA, Urriola, N, Lee, MW, Sussman, GL, Levi, G, Gould, W, Ferrie, P, Rosenberg, E, Waserman, S, O'Quinn, J, Gagnon, R, Vachova, M, Stauerbach-Renz, P, Weber, A, Zimmer, S, Gilfert, T, Lang, B, Escuriola-Ettingshausen, C, Maurer, M, Metz, M, Schoepke, N, Altrichter, S, Hawro, T, Schwabe, D, Graff, J, Behrens, F, Kohm, M, Andarawewa, S, Temesszentandrasi, G, Kohalmi, VK, Kidon, M, Kadar, L, Benor, S, Bonanni, E, Wu, M, Zanichelli, A, Mansi, M, Rizzotto, A, Giardino, F, Fidone, F, Varga, M, Iftene, M, Badiu-Tisa, ID, Cabanas, R, Pedrosa, M, Rivero-Paparoni, D, Gomez-Traseira, C, Alvez, A, Phillips, E, Prieto, A, Zubeldia, J, Ibanez, E, Almero, R, Buckland, M, Grigoriadou, S, Manson, A, Yeatman, N, Laffan, J, Nasr, I, Ghurye, R, Rehman, T, Schaeffer, C, Ghaffari, G, Kelbel, T, Reddy, V, Buyantseva, L, Mende, C, Jose, J, Novchicht, T, Li, HH, Scarupa, M, Economides, A, White, M, Kaliner, M, Ward, C, Shaikh, S, Johnson, T, Kosh, L, Dauphin, P, Baker, J, Persons, S, Newman, A, Noonan, MJ, Lumry, WR, Poarch, KP, Tucker, J, Aguilar, D, Noth, D, Bernstein, J, Bernstein, D, Evans, S, Crawford, M, McGuckin, SD, McCollum, JR, Bradley, B, Wagner, C, Cartwright, A, Bonner, J, Soong, W, Sikora, M, Lemke, M, Luthin, P, Youngblood, B, DeBerry, E, Gilbert, E, Zhao, W, Ward, B, Alvarez, A, Kumar, S, Akl, E, Curl, J, Silva, K, Mostofi, T, Schultz, N, Manning, ME, Davis, A, Nelson, J, Levy, DS, Christiansen, SC, and COMPACT Investigators

Subjects
Hereditary angioedema, HAEGARDA, Long-term, Prophylaxis, Subcutaneous, Safety, C1-esterase inhibitor
Abstract

BACKGROUND: For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH [SC]; HAEGARDA, CSL Behring) was established in the 16-week Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT). OBJECTIVE: To assess the long-term safety, occurrence of angioedema attacks, and use of rescue medication with C1-INH(SC). METHODS: Open-label, randomized, parallel-arm extension of COMPACT across 11 countries. Patients with frequent angioedema attacks, either study treatment-naive or who had completed COMPACT, were randomly assigned (1:1) to 40 IU/ kg or 60 IU/kg C1-INH(SC) twice per week, with conditional uptitration to optimize prophylaxis (ClinicalTrials.gov registration no. NCT02316353). RESULTS: A total of 126 patients with a monthly attack rate of 4.3 in 3 months before entry in COMPACT were enrolled and treated for a mean of 1.5 years; 44 patients (34.9%) had more than 2 years of exposure. Mean steady-state C1-INH functional activity increased to 66.6% with 60 IU/kg. Incidence of adverse events was low and similar in both dose groups (11.3 and 8.5 events per patient-year for 40 IU/kg and 60 IU/kg, respectively). For 40 IU/kg and 60 IU/kg, median annualized attack rates were 1.3 and 1.0, respectively, and median rescue medication use was 0.2 and 0.0 times per year, respectively. Of 23 patients receiving 60 IU/kg for more than 2 years, 19 (83%) were attack-free during months 25 to 30 of treatment. CONCLUSIONS: In patients with frequent HAE attacks, long-term replacement therapy with C1-INH(SC) is safe and exhibits a substantial and sustained prophylactic effect, with the vast majority of patients becoming free from debilitating disease symptoms. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

Published
2019

24. Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

Author

Bygum A, Caballero T, Grumach A, Longhurst H, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M, Delaunay C, Boccon-Gibod I, Coppere B, Du Thanh A, Dzviga C, Fain O, Goichot B, Gompel A, Guez S, Jeandel P, Kanny G, Launay D, Maillard H, Martin L, Masseau A, Ollivier Y, Sobel A, Aygoren-Pursun E, Bas M, Bauer M, Bork K, Greve J, Magerl M, Martinez-Saguer I, Strassen U, Papadopoulou-Alataki E, Psarros F, Graff Y, Kivity S, Reshef A, Toubi E, Arcoleo F, Bova M, Cicardi M, Nconi P, Marone G, Montinaro V, Triggiani M, Baeza M, Cabanas R, Guilarte M, Hernandez D, de Larramendi C, Lleonart R, Lobera T, Marques L, Pedro B, Bjorkander J, Bethune C, Garcez T, and IOS Study Grp

Subjects
Hereditary angioedema, Elderly, Icatibant Outcome Survey, Safety
Abstract

Background: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. Methods: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of icatibant. We conducted descriptive analyses in younger (age < 65 years) versus elderly patients (age >= 65 years). Here, we report patient characteristics and safety-related findings. Results: As of February 2018, 872 patients with C1-INH-HAE type I/II were enrolled, of whom 100 (11.5%) were >= 65 years old. Significant differences between elderly versus younger patients, respectively, were noted for median age at symptom onset (17.0 vs 12.0 years), age at diagnosis (41.0 vs 19.4 years), and delay between symptom onset and diagnosis (23.9 vs 4.8 years) (P

Published
2019

25. Deletions or duplications in KCNQ2 can cause benign familial neonatal seizures

Author

Heron, S.E., Cox, K., Grinton, B.E., Zuberi, S.M., Kivity, S., Afawi, Z., Straussberg, R., Berkovic, S.F., Scheffer, I.E., and Mulley, J.C.

Subjects
Convulsions -- Causes of, Convulsions -- Demographic aspects, Potassium channels -- Genetic aspects, Potassium channels -- Health aspects, Familial diseases -- Genetic aspects, Familial diseases -- Research, Gene mutations -- Health aspects, Infants (Newborn) -- Diseases, Infants (Newborn) -- Research, Health
Published
2007

26. Quantitative analysis of phenotypic elements augments traditional electroclinical classification of common familial epilepsies

Author

Abou-Khalil, B, Afawi, Z, Allen, AS, Bautista, JF, Bellows, ST, Berkovic, SF, Bluvstein, J, Burgess, R, Cascino, G, Cossette, P, Cristofaro, S, Crompton, DE, Delanty, N, Devinsky, O, Dlugos, D, Ellis, CA, Epstein, MP, Fountain, NB, Freyer, C, Geller, EB, Glauser, T, Glynn, S, Goldberg-Stern, H, Goldstein, DB, Gravel, M, Haas, K, Haut, S, Heinzen, EL, Kirsch, HE, Kivity, S, Knowlton, R, Korczyn, AD, Kossoff, E, Kuzniecky, R, Loeb, R, Lowenstein, DH, Marson, AG, McCormack, M, McKenna, K, Mefford, HC, Motika, P, Mullen, SA, O'Brien, TJ, Ottman, R, Paolicchi, J, Parent, JM, Paterson, S, Petrou, S, Petrovski, S, Pickrell, WO, Poduri, A, Rees, MI, Sadleir, LG, Scheffer, IE, Shih, J, Singh, R, Sirven, J, Smith, M, Smith, PEM, Thio, LL, Thomas, RH, Venkat, A, Vining, E, Von Allmen, G, Weisenberg, J, Widdess-Walsh, P, Winawer, MR, Abou-Khalil, B, Afawi, Z, Allen, AS, Bautista, JF, Bellows, ST, Berkovic, SF, Bluvstein, J, Burgess, R, Cascino, G, Cossette, P, Cristofaro, S, Crompton, DE, Delanty, N, Devinsky, O, Dlugos, D, Ellis, CA, Epstein, MP, Fountain, NB, Freyer, C, Geller, EB, Glauser, T, Glynn, S, Goldberg-Stern, H, Goldstein, DB, Gravel, M, Haas, K, Haut, S, Heinzen, EL, Kirsch, HE, Kivity, S, Knowlton, R, Korczyn, AD, Kossoff, E, Kuzniecky, R, Loeb, R, Lowenstein, DH, Marson, AG, McCormack, M, McKenna, K, Mefford, HC, Motika, P, Mullen, SA, O'Brien, TJ, Ottman, R, Paolicchi, J, Parent, JM, Paterson, S, Petrou, S, Petrovski, S, Pickrell, WO, Poduri, A, Rees, MI, Sadleir, LG, Scheffer, IE, Shih, J, Singh, R, Sirven, J, Smith, M, Smith, PEM, Thio, LL, Thomas, RH, Venkat, A, Vining, E, Von Allmen, G, Weisenberg, J, Widdess-Walsh, P, and Winawer, MR

Abstract

OBJECTIVE: Classification of epilepsy into types and subtypes is important for both clinical care and research into underlying disease mechanisms. A quantitative, data-driven approach may augment traditional electroclinical classification and shed new light on existing classification frameworks. METHODS: We used latent class analysis, a statistical method that assigns subjects into groups called latent classes based on phenotypic elements, to classify individuals with common familial epilepsies from the Epi4K Multiplex Families study. Phenotypic elements included seizure types, seizure symptoms, and other elements of the medical history. We compared class assignments to traditional electroclinical classifications and assessed familial aggregation of latent classes. RESULTS: A total of 1120 subjects with epilepsy were assigned to five latent classes. Classes 1 and 2 contained subjects with generalized epilepsy, largely reflecting the distinction between absence epilepsies and younger onset (class 1) versus myoclonic epilepsies and older onset (class 2). Classes 3 and 4 contained subjects with focal epilepsies, and in contrast to classes 1 and 2, these did not adhere as closely to clinically defined focal epilepsy subtypes. Class 5 contained nearly all subjects with febrile seizures plus or unknown epilepsy type, as well as a few subjects with generalized epilepsy and a few with focal epilepsy. Family concordance of latent classes was similar to or greater than concordance of clinically defined epilepsy types. SIGNIFICANCE: Quantitative classification of epilepsy has the potential to augment traditional electroclinical classification by (1) combining some syndromes into a single class, (2) splitting some syndromes into different classes, (3) helping to classify subjects who could not be classified clinically, and (4) defining the boundaries of clinically defined classifications. This approach can guide future research, including molecular genetic studies, by identifyi

Published
2019

30. Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant:findings from the Icatibant Outcome Survey

Author

Aberer, Werner, Maurer, Marcus, Bouillet, Laurence, Zanichelli, Andrea, Caballero, Teresa, Longhurst, Hilary J., Perrin, Amandine, Andresen, Irmgard, Wiednig, M., Grumach, A., Bygum, A., Blanchard Delauny, C., Boccon-Gibod, I., Coppere, B., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P. Y., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Arnolds, J., Aygören-Pürsün, E., Bas, M., Bauer, M., Bork, K., Magerl, M., Martinez-Saguer, I., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Montinaro, V., Marone, G., Baeza, M. L., Cabañas, R., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marques, L., Saenz de San Pedro, B., Bjoerkander, J., Bethune, C., Garcez Pereira, T., Helbert, M., Aberer, Werner, Maurer, Marcu, Bouillet, Laurence, Zanichelli, Andrea, Caballero, Teresa, Longhurst, Hilary J., Perrin, Amandine, Andresen, Irmgard, Wiednig, M., Grumach, A., Bygum, A., Blanchard Delauny, C., Boccon-Gibod, I., Coppere, B., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P. Y., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Arnolds, J., Aygören-Pürsün, E., Bas, M., Bauer, M., Bork, K., Magerl, M., Martinez-Saguer, I., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Montinaro, V., Marone, G., Baeza, M. L., Cabañas, R., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marques, L., Saenz de San Pedro, B., Bjoerkander, J., Bethune, C., Garcez Pereira, T., and Helbert, M.

Subjects
lcsh:Immunologic diseases. Allergy, Pulmonary and Respiratory Medicine, Breakthrough attack, Immunology, Attack rate, Time to treatment, Long term prophylaxis, Bradykinin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Icatibant, Immunology and Allergy, Medicine, In patient, 030212 general & internal medicine, Prophylaxi, Breakthrough attacks, Hereditary angioedema, business.industry, Prophylaxis, Research, musculoskeletal, neural, and ocular physiology, General Medicine, medicine.disease, Rescue medication, Treatment characteristics, 030228 respiratory system, chemistry, nervous system, Anesthesia, lcsh:RC581-607, business
Abstract

BACKGROUND: Patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) experience recurrent attacks of cutaneous or submucosal edema that may be frequent and severe; prophylactic treatments can be prescribed to prevent attacks. However, despite the use of long-term prophylaxis (LTP), breakthrough attacks are known to occur. We used data from the Icatibant Outcome Survey (IOS) to evaluate the characteristics of breakthrough attacks and the effectiveness of icatibant as a treatment option.METHODS: Data on LTP use, attacks, and treatments were recorded. Attack characteristics, treatment characteristics, and outcomes (time to treatment, time to resolution, and duration of attack) were compared for attacks that occurred with versus without LTP.RESULTS: Data on 3228 icatibant-treated attacks from 448 patients with C1-INH-HAE were analyzed; 30.1% of attacks occurred while patients were using LTP. Attack rate, attack severity, and the distribution of attack sites were similar across all types of LTP used, and were comparable to the results found in patients who did not receive LTP. Attacks were successfully treated with icatibant; 82.5% of all breakthrough attacks were treated with a single icatibant injection without C1-INH rescue medication. Treatment outcomes were comparable for breakthrough attacks across all LTP types, and for attacks without LTP.CONCLUSIONS: Patients who use LTP should be aware that breakthrough attacks can occur, and such attacks can be severe. Thus, patients with C1-INH-HAE using LTP should have emergency treatment readily available. Data from IOS show that icatibant is effective for the treatment of breakthrough attacks. Trial Registration NCT01034969.

Published
2017
Full Text
View/download PDF

36. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study

Author

Lumry, William R., primary, Martinez-Saguer, Inmaculada, additional, Yang, William H., additional, Bernstein, Jonathan A., additional, Jacobs, Joshua, additional, Moldovan, Dumitru, additional, Riedl, Marc A., additional, Johnston, Douglas T., additional, Li, H. Henry, additional, Tang, Yongqiang, additional, Schranz, Jennifer, additional, Lu, Peng, additional, Vardi, Moshe, additional, Farkas, Henriette, additional, Keith, P., additional, Yang, W., additional, Maurer, M., additional, Martinez-Saguer, I., additional, Farkas, H., additional, Reshef, A., additional, Kivity, S., additional, Moldovan, D., additional, Caballero, T., additional, Guilarte, M., additional, Hernandez, M.D., additional, González-Quevedo, M.T., additional, Banerji, A., additional, Bernstein, J., additional, Bewtra, A., additional, Craig, T., additional, Fineman, S., additional, Gower, R., additional, Jacobs, J., additional, Johnston, D., additional, Kashkin, J., additional, Li, H.H., additional, Lumry, W.R., additional, Manning, M., additional, McNeil, D., additional, Melamed, I., additional, Mumneh, N., additional, Nickel, T., additional, Panuto, J., additional, Soteres, D., additional, Tachdjian, R., additional, Offenberger, J., additional, and Wedner, J., additional

Published
2019
Full Text
View/download PDF

39. Early-Onset Benign Occipital Seizure Susceptibility Syndrome

Author

Ferrie, C. D., Beaumanoir, A., Guerrini, R., Kivity, S., Vigevano, F., Takaishi, Y., Watanabe, K., Mira, L., Capizzi, G., Costa, P., Valseriati, D., Grioni, D., Lerman, P., Ricci, S., Vigliano, P., Goumas-Kartalas, A., Hashimoto, K., Robinson, R. O., and Panayiotopoulos, C. P.

Published
1997

41. Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects: Rome, Italy/Vatican City. 27-29 April 2017

Author

Traina G, Valluzzi RL, Fierro V, Riccardi C, Artesani MC, De Vuono A, Fiocchi A, Martelli AG, Ríos LA, Alcocer CR, Navarrete E, Del Rio Navarro BE, Gonzalez V, Velasco B, Perez Aviles HJ, Fernandez RJ, Pozo FC, Farhan AJ, Arshad H, Hussain A, Sharikadze O, Okhotnikova O, Alcover J, Rodríguez Rius D, Pineda F, Dalal I, Weinbrand-Goichberg J, Benor S, Rottem M, Kivity S, Sato S, Yanagida N, Ebisawa M, Umanets T, Antipkin Y, Barzylovich V, Lapshyn V, Umanets M, Yuriev S, Rodriguez D, Bekir S, Pincock T, Vieira Hernandez A, Capriles Hulett A, Sánchez Borges M, Fabiano F, Albarran C, Goyal R, Gupta S, Gaurav G, Luskin AT, Griffin NM, Wagelie-Steffen A, Trzaskoma BL, Limb SL, Busse WW, Zeiger RS, Gonzalez-Reyes E, Casale TB, Chipps BE, Sugizaki C, Goto F, Yamaide A, Mitsunaga K, Tomiita M, Hoshioka A, Shimojo N, Pop LL, Ciuca IM, Tamas L, Lazarescu M, Pienar C, Yamaide F, Fikri B, Sato H, Okishima N, Kobayashi M, Takai M, Nishigata K, Yoda R, Oana YT, Kajiwara C, Shimodaira M, Suzuki T, Iizawa H, Kamijo K, Karmakar B, Bhattacharya SG, Blohlávková S, Kopelentová E, Víšek P, Štádler J, Šetinová I, Novobílská J, Lundelin K, Salminen S, Isolauri E, Pitt T, Flanders T, Peñalver M, Martínez P, Lluch-Canut T, Malet A, Nam YH, Jin HJ, Lee SK, Kulalert P, Sritipsukho P, Pathumanond J, Baynova K, Labella M, De Aramburu T, Prados M, Haanpää L, Aarnio J, Nermes M, Af Ursin P, Kaljonen A, Bala N, Bhagwat K, Hindley J, Chapman M, Baalasubramanian S, Besednjak-Kocijancic L, SenGupta K, Antonova E, Kong AM, Iqbal A, Teague WG, Ortiz B, Paknis B, Rosen K, Szefler S, Alblooshi A, Al-Hammadi S, Vega A, Gutiérrez-Rivas R, Alonso AM, Beitia JM, Belén Mateo M, Cárdenas R, García-Domínguez JJ, Pitchon Dos Reis R, Gonçalves Alvim C, Andrade C, Reis A, Ribeiro H, Panaitescu Bunu C, Marusciac L, Paralescu S, Tamas P, Martí Guadaño E, Escobar Bolaños C, Martí José N, Pau Casanovas P, Biarnés Rib G, Castells M, de Vicente Jiménez T, Mennini M, De Angelis P, Rea F, Malamisura M, Tambucci R, Dall'Oglio L, Del Chierico F, Napolitano T, Reddel S, Vernocchi P, D'Ambrosio A, Putignani L, Dahdah L, Banzato C, Plaza-Martín AM, Bosque García M, Íbero M, Mazzina O, Marzano V, Pecora V, Koch P, Valentini D, Santamaria F, Mukherjee A, Kandhare A, and Bodhankar S

Published
2017

46. Tuftsin–phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model

Author

Shemer, A, primary, Kivity, S, additional, Shovman, O, additional, Bashi, T, additional, Perry, O, additional, Watad, A, additional, Ben-Ami Shor, D, additional, Volkov, A, additional, Barshack, I, additional, Bragazzi, N L, additional, Krule, A, additional, Fridkin, M, additional, Amital, H, additional, Blank, M, additional, and Shoenfeld, Y, additional

Published
2018
Full Text
View/download PDF

47. Frequency of CNKSR2 mutation in the X-linked epilepsy-aphasia spectrum

Author

Damiano, JA, Burgess, R, Kivity, S, Lerman-Sagie, T, Afawi, Z, Scheffer, IE, Berkovic, SF, Hildebrand, MS, Damiano, JA, Burgess, R, Kivity, S, Lerman-Sagie, T, Afawi, Z, Scheffer, IE, Berkovic, SF, and Hildebrand, MS

Abstract

Synaptic proteins are critical to neuronal function in the brain, and their deficiency can lead to seizures and cognitive impairments. CNKSR2 (connector enhancer of KSR2) is a synaptic protein involved in Ras signaling-mediated neuronal proliferation, migration and differentiation. Mutations in the X-linked gene CNKSR2 have been described in patients with seizures and neurodevelopmental deficits, especially those affecting language. In this study, we sequenced 112 patients with phenotypes within the epilepsy-aphasia spectrum (EAS) to determine the frequency of CNKSR2 mutation within this complex set of disorders. We detected a novel nonsense mutation (c.2314 C>T; p.Arg712*) in one Ashkenazi Jewish family, the male proband of which had a severe epileptic encephalopathy with continuous spike-waves in sleep (ECSWS). His affected brother also had ECSWS with better outcome, whereas the sister had childhood epilepsy with centrotemporal spikes. This mutation segregated in the three affected siblings in an X-linked manner, inherited from their mother who had febrile seizures. Although the frequency of point mutation is low, CNKSR2 sequencing should be considered in families with suspected X-linked EAS because of the specific genetic counseling implications.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results